Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age

• Main Authors: Anna Lisa Ong-Lim (Author), Georgi Shukarev (Author), Mitzi Trinidad-Aseron (Author), Delia Caparas-Yu (Author), Astrid Greijer (Author), Michel Duchene (Author), Gert Scheper (Author), Vitalija van Paassen (Author), Mathieu Le Gars (Author), Conor P. Cahill (Author), Hanneke Schuitemaker (Author), Macaya Douoguih (Author), Jeanne-Marie Jacquet (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to receive one of 3 dose levels of sIPV or a conventiona...